This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (10)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Radiation Therapy  • Randomized Controlled Trial  • Alert me on articles by topic

A Randomized Trial

Anthony V. D’Amico, MD, PhD; Ming-Hui Chen, PhD; Andrew A. Renshaw, MD; Marian Loffredo, RN, OCN; Philip W. Kantoff, MD

JAMA. 2008;299(3):289-295.

Context  Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST).

Objectives  To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality.

Design, Setting, and Patients  At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test.

Main Outcome Measure  Time to all-cause mortality.

Results  As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause mortality (44 vs 30 deaths; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P = .01) was observed in men randomized to RT compared with RT and AST. However, the increased risk in all-cause mortality appeared to apply only to men randomized to RT with no or minimal comorbidity (31 vs 11 deaths; HR, 4.2; 95% CI, 2.1-8.5; P < .001). Among men with moderate or severe comorbidity, those randomized to RT alone vs RT and AST did not have an increased risk of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI, 0.27-1.10; P = .08).

Conclusions  The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction.

Trial Registration  clinicaltrials.gov Identifier: NCT00116220

Author Affiliations: Departments of Radiation Oncology (Dr D’Amico and Ms Loffredo), Pathology (Dr Renshaw), and Medical Oncology (Dr Kantoff), Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts; and Department of Statistics, University of Connecticut, Storrs (Dr Chen).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long term androgen deprivation therapy in prostate cancer
Ockrim and Abel
BMJ 2008;337:a1361-a1361.
FULL TEXT  

In Reply
Nguyen and D'Amico
JCO 2008;26:3817-3818.
FULL TEXT  

The Genetics of Castration-Resistant Prostate Cancer: What Can the Germline Tell Us?
Sharifi et al.
Clin. Cancer Res. 2008;14:4691-4693.
ABSTRACT | FULL TEXT  

All you need to read in the other general journals
BMJ 2008;336:242-243.
FULL TEXT  

Radiation Therapy With or Without Hormonal Therapy for Prostate Cancer
JWatch Oncology and Hematology 2008;2008:1-1.
FULL TEXT